BenevolentAI Results Presentation Deck
BEN-8744 results and progress to date
Target
validation
2019
2020
2021
Novel, potent advanced lead molecule developed within 2 years
TARGET IDENTIFICATION
Novel target for UC
Discovered using Benevolent
TargetID tools
✓ PDE10 has zero linkage to UC in
all available biomedical literature
✓ Experimentally validated in
ex-vivo UC colon samples from
patients refractory to SoC treatment
Candidate nominated
CHEMISTRY
Rapid and efficient lead
optimisation
✓ Molecular Design tools enabled
rapid and efficient lead optimisation
✔ Candidate nominated in Sep '21
Novel, potent, selective, peripherally
restricted PDE10. Inhibitor, with low
dose prediction
Delivered drug candidate within
2 years from programme initiation
BenevolentAl Proprietary
2022
2023
Preclinical development
CTA Filed
Phase I
clinical study
CLINICAL DEVELOPMENT
Developing responder and
progression endotypes
We will develop responder and
progression endotypes, adding
molecular descriptors
✓ These will inform our trial design,
patient selection and further target
identification in UC
✓ Augmenting a further loop of
iteration on an enriched graph
Benevolent 21View entire presentation